The article discusses the potential growth of GLP-1 medications, such as Ozempic, in the US market, estimating that over 100 million Americans could benefit from these drugs. The market for obesity medication has a troubled past, but GLP-1s appear to be a successful solution, with estimates suggesting they can reduce body weight by at least 15%. However, supply shortages have plagued the market, and it's unlikely that demand will be met in the near term. The article forecasts the growth of GLP-1s over the next six years, considering factors such as sales, prescriptions, and supply constraints.